| Merck (US)–Cyprumed: drug delivery technology, 202504– license + option agreem for oral drug delivery of peptide therapeutics |
2025-04-15 |
| Immunic–SEVERAL: investment, 202504 registered directed offering $5.1m led by Aberdeen Investments with 5.67m shares common stock at $0.9/share |
2025-04-09 |
| Bico–Sartorius: investment, 202404– acquisition 100% of MatTek Corp + Visikol Inc on cash/debt-free basis for $80m by Sartorius Lab Holding GmbH |
2025-04-04 |
| Dotmatics–Siemens: investment, 202402– acquisition $5.1b of Dotmatics from Insight Partners ANNOUNCED |
2025-04-02 |
| AIRNA–SEVERAL: investment, 202504 financing round Series B $155m led by Venrock HCP + co-led by Forbion Growth |
2025-04-01 |
| Navigo Proteins–SCK CEN (BE): radiopharmaceuticals, 202504– strategic RnD collab radiotheranostics using radioisotope 161Tb + Affilin + HEAD platforms |
2025-04-01 |
| Bayer–Puhe BioPharma: PRMT5 inhibitor, 202503– license ww excl €na to PH020 / BAY 3713372 from Suzhou Puhe BioPharma Co Ltd |
2025-03-26 |
| Amboss–SEVERAL: investment, 202503 financing round €240m led by Kirkbi + M&G Investments + Lightrock |
2025-03-25 |
| Eversyn–SEVERAL: investment, 202503 seed financing round €1.6m led by bmp Ventures with IBG funds |
2025-03-20 |
| Meliodays Medical–SEVERAL: investment, 202503 pre-seed financing round >€800k led by Capacura |
2025-03-20 |
| Roche–Oxford BioTherapeutics: antibody cancer drugs, 202503– collab strategic $36m upfront + >$1b milestones using OGAP Verify for Ab cancer drugs |
2025-03-19 |
| Araris Biotech–Otsuka: investment, 202503– acquisition $400m upfront + $740m milestones of Araris Biotech AG by Taiho Pharmaceutical Co Ltd |
2025-03-17 |
| Vantis–SEVERAL: investment, 202503 financing round Series A €10m led by Angelini Ventures |
2025-03-12 |
| Epoch Biodesign–SEVERAL: investment, 202503 financing round Series A $17.3m led by Extantia Capital |
2025-03-05 |
| OmicScouts–Momentum Biotechnologies: investment, 202503 acquisition of OmicScouts GmbH by Momentum Biotechnologies |
2025-03-05 |
| Trimtech Therapeutics–SEVERAL: investment, 202503 seed financing round £25m led by Cambridge Innovationn Capital + DDF |
2025-03-05 |
| Xund Solutions–SEVERAL: investment, 202503 financing round pre-Series A €6m led by Lead Ventures |
2025-03-05 |
| Callio Therapeutics–SEVERAL: investment, 202503 financing round Series A $187m led by founding investor Frazier Life Sciences |
2025-03-03 |
| Sionna Therapeutics–TD Bank: investor conference, 202503 supply service Sionna presents at TD Cowen Health Care Conference 2025 |
2025-03-03 |
| GQ Bio Therapeutics–Pacira: investment, 202502 acquisition remaining 81% in GQ Bio for $32m by Pacira |
2025-02-27 |
| Adoram Therapeutics–SEVERAL: investment, 202502 pre-seed financing round led by private business angels + Ipalmetrix + Fongit |
2025-02-25 |
| VeroVaccines–SEVERAL: investment, 202502 financing round Series €1.6m from existing investors + founders |
2025-02-25 |
| Bluebird Bio–Carlyle: investment, 202502– acquisition of Bluebird Bio by funds managed by Carlyle + SK Capital Partners + delisting |
2025-02-21 |
| In Virtuo Laboratories–SEVERAL: investment, 202502 1st financing round €2.85m of InVirtuoLabs |
2025-02-20 |
| Atai Life Sciences–SEVERAL: investment, 202502 public offering $55m+$8.25m with 26.19m+3.93m common shares at $2.1/share |
2025-02-19 |
| Anbio Biotechnology–SEVERAL: investment, 202502 IPO $8m net $7.44m at Nasdaq Global Market with 1.6m Class A ordinary shares at $5/share |
2025-02-18 |
| DeepEn–SEVERAL: investment, 202502 seed financing round € 7-digit from bm|t + MBG Thüringen + Sparkasse-Jena-Holzland |
2025-02-17 |
| Bambusa Therapeutics–SEVERAL: investment, 202502 financing round Series A $90m led by new investor RA Capital Management |
2025-02-14 |
| Green Elephant Biotech–Bürkert Fluidic Control Systems: investment, 202502 strategic investment by Bürkert as part of strategic partnership |
2025-02-13 |
| Newronika–SEVERAL: investment, 202502 financing round Series B €13.6m led by Fondazione ENEA Tech e Biomedical |
2025-02-13 |
| Oculis–SEVERAL: investment, 202502 underwritten offering $100m with 5m ordinary shares at $20/share |
2025-02-13 |
| Phaeosynt–SEVERAL: investment, 202502 seed financing round €1.7m from existing + new investors |
2025-02-12 |
| Anthos Therapeutics–Novartis: investment, 2020502– acquisition $925m upfront + $2.15b milestones by Novartis from majority owner Blackstone LS et al |
2025-02-11 |
| Avelios Medical–SEVERAL: investment, 202502 financing round Series A €30m led by Sequoia Capital |
2025-02-06 |
| Akribion–SEVERAL: investment, 202502 seed financing round €8m led by Carma Fund + RV Invest |
2025-02-04 |
| Knauer–Labomatic Instruments: liquid chromatography 202502– collab strategic combining HPLC offerings to customers incl sales + service |
2025-02-03 |
| Arctic Therapeutics–SEVERAL: investment, 202501 financing round Series A €26.5m |
2025-01-22 |
| Candor Bioscience–Medix Biochemica: investment, 202501 acquisition of Candor Bioscience GmbH by Medix Biochemica |
2025-01-22 |
| 4basebio–Circio: synthetic DNA vectors, 202501– collab developm integration of circVEC system with Hermes platform + hpDNA + opDNA |
2025-01-21 |
| Bureau Veritas–SGS: investment, 202501– confirmed merger discussion |
2025-01-15 |
| Ariceum Therapeutics–ITM: radiopharmaceuticals, 202501– supply €na of n.c.a.Ac-225 for Ariceum radiopharma candidates by Actineer |
2025-01-13 |
| Bruker–JPMorgan Chase: investor conference, 202501 supply service Bruker presents at JP Morgan Healthcare Conference 2025 |
2025-01-13 |
| Daiichi Sankyo–Glycotope: antibody-drug conjugates, 202501 acquisition all IPRs $132.5m for use of gatipotuzumab in ADC DS-3939 |
2025-01-13 |
| IBA Lifesciences–Cube Biotech: investment, 202501 acquisition of IBA Lifesciences by Cube Biotech backed by majority owner Archimed |
2025-01-13 |
| IDRx–GSK: investment, 202501– acquisition 100% of IDRx for $1b upfront + $150m milestones by GSK |
2025-01-13 |
| ITM–JPMorgan Chase: investor conference, 202501 supply service ITM presents at JP Morgan Healthcare Conference 2025 |
2025-01-13 |
| Windward Bio–SEVERAL: investment, 202501 financing round Series A $200m led by OrbiMed + Novo Holdings + Blue Owl Healthcare Opportunities |
2025-01-10 |
| Boehringer–Lonza: ADC technology, 202501– license to Synaffix ADC technology €na upfront + $1.3b milestones plus royalties |
2025-01-09 |
| Graph Therapeutics–SEVERAL: investment, 202501 pre-seed financing round $3.1m led by Squareone + Merantix Capital |
2025-01-09 |
| Numab–SEVERAL: investment, 202501 financing round Series C extension CHF50m bringing total Series C to CHF180m |
2025-01-09 |
| Alesta Therapeutics–SEVERAL: investment, 202501 financing round Series A €65m co-led by Frazier Life Sciences + Droia Ventures |
2025-01-08 |
| Orbis Medicines–SEVERAL: investment, 202501 financing round Series €90m led by NEA |
2025-01-06 |
| Roche–Innovent Biologics: antibody-drug conjugate, 202501– collab + excl ww license to IBI3009 with $80m upfront + $1b milestones plus royalties |
2025-01-02 |
| Gemma Biotherapeutics–SEVERAL: investment, 202412 seed financing round $34m led by Doube Point Ventures + Bioluminescence Ventures + Earlybird VC |
2024-12-23 |
| Univ Zurich–Bruker: NMR spectrometer, 202412 supply 1.2 GHz Ascend NMR spectrometer to Swiss High-field NMR Facility at UZH |
2024-12-20 |
| Novartis–BioAge Labs: drug target discovery, 202412– collab multi-year $20m upfront + $530m milestones identify targets for age-related diseases |
2024-12-18 |
| HUB Organoids–Merck (DE): investment, 202412– acquisition €na of HUB Organoids Holding BV by Merck SIGNED |
2024-12-17 |
| Formo Bio–EU (govt): credit, 202412– venture debt loan €35m from EIB |
2024-12-16 |
| Mainz Biomed–SEVERAL: investment, 202412 follow-on offering $8m with 1.37m units (1 share + 1 Class A + 1 Class B warrant) at $5.85/unit |
2024-12-16 |
| RhyGaze–SEVERAL: investment, 202412 financing round Series A $86m led by GV |
2024-12-13 |
| Andera Partners–New York Life: investment, 202412– acquisition €na of 40% minority share in Andera by New York Life Investments |
2024-12-12 |
| Fresenius–Ori Biotech: CGT manufacturing technology, 202412– collab integration IRO platform with up + downstream processing tech of Fresenius Kabi |
2024-12-10 |
| Citryll–SEVERAL: investment, 202412 financing round Series B €85m co-led by JnJ JJDC + Forbion + Novartis Venture Fund |
2024-12-09 |
| Ariceum Therapeutics–Eckert & Ziegler: radionuclides, 202412– supply agreem ww for Ac-225 + Lu-177 to Ariceum |
2024-12-05 |
| Bruker–Ion Opticks: liquid chromatography, 202412– supply costum chromatography column for MS-based proteomic services to Biognosys |
2024-12-05 |
| Antag Therapeutics–SEVERAL: investment, 202412 financing round Series A €80m led by Versant Ventures |
2024-12-04 |
| HexagonFab–SEVERAL: investment, 202412 financing round Series A £6.6m of Abselion led by M Ventures |
2024-12-04 |
| Eppendorf–DataHow: laboratory software, 202412– collab strategic integration of DataHowLab s/w with BioNSight cloud |
2024-12-02 |
| Carl Roth–Bio Inx: bioinks, 202411– distribution ww of entire portfolio of bioinks of Bio Inx by Carl Roth |
2024-11-27 |
| Cradle Bio–SEVERAL: investment, 202411 financing round Series B $73m led by IVP |
2024-11-26 |
| Eisbach Bio–Texas (govt): grant, 202411 CPRIT grant $4.75m to support Ph1/2 study of EIS-12656 at MD Anderson |
2024-11-26 |
| Kyan Health–SEVERAL: investment, <202411 seed financing round $4m led by Amplo VC |
2024-11-26 |
| Poseida Therapeutics–Roche: investment, 202411– acquisition $1b in cash + up to $500k in CVRs by Roche |
2024-11-26 |
| Baccinex–Adragos Pharma: investment, 202411 acquisition €na of Baccinex by Adragos Pharma |
2024-11-25 |
| Bico–RAG: investment, 202411 acquisition €26m of Nanoscribe from Bico Group by LAB14 GmbH |
2024-11-21 |
| Kate Therapeutics–Novartis: investment, 202411 acquisition up to $1.1b incl upfront cash payment + milestones by Novartis |
2024-11-21 |
| Pep2Tango Therapeutics–Versant Venures: investment, 202411 investment round €na with Versant Ventures |
2024-11-21 |
| CRISPR Therapeutics–Leucadia: investor conference, 202411 supply service CRISPR Tx presents at Jefferies London Healthcare Conference |
2024-11-20 |
| Evotec–Halozyme: investment, 202411 acquisition €2b unsolicited + non-binding cash offer at €11/share refused + withdrawn NOT REALISED |
2024-11-14 |
| Biotheus–BioNTech: investment, 202411– acquisition 100% for $800m upfront mostly in cash + few ADSs plus $150m milestones |
2024-11-13 |
| Centogene–Charme Capital Partners: investment, 202411–202503 acquisition €8.7m of sole operating subsidiary Centogene GmbH by Charme Capital |
2024-11-13 |
| Alentis Therapeutics–SEVERAL: investment, 202411 financing round Series D $181.4m led by OrbiMed with co-leads Novo Holdings + Jeito Capital |
2024-11-12 |
| CRISPR Therapeutics–Guggenheim: investor conference, 202411 supply service CRISPR Tx to present at Guggenheim Healthcare Innovation Conference |
2024-11-12 |
| Mainz Biomed–Thermo Fisher: colorectal cancer screening test, 202411– collab developm + commercialisation assays for mRNA-based CRC screening tests |
2024-11-12 |
| Mediaire–SEVERAL: investment, 202411 financing round €12m led by LBO France |
2024-11-12 |
| Zymofix–SEVERAL: investment, 202411 financing round €2m led by HTGF |
2024-11-12 |
| Complihealth–Bertelsmann: investment, <=202411 investment by new investor Bertelsmann Investments in Guardoc Health |
2024-11-07 |
| PrognomiQ–SEVERAL: investment, 202411 financing round Series D $34m led by Seer Inc |
2024-11-05 |
| Nuuron–SEVERAL: investment, 202410 seed financing round €3.5m led by HTGF |
2024-10-31 |
| Aignostics–SEVERAL: investment, 202410 financing round Series B $34m led by Athos |
2024-10-29 |
| Inbrain Neuroelectronics–SEVERAL: investment, 202410 financing round Series B $50m led by imec.xpand |
2024-10-29 |
| Kynos Therapeutics–Falk Pharma: investment, 202410 acquisition of Kyno Therapeutics Ltd by Dr Falk Pharma GmbH |
2024-10-29 |
| Kivu Bioscience–SEVERAL: investment, 202410 financing round Series A $92m led by Novo Holdings |
2024-10-28 |
| Agomab–SEVERAL: investment, 202410 financing round Series D $89m (€82.1m) incl new investors Sanofi + Invus |
2024-10-25 |
| UpNano–SEVERAL: investment, 202410 financing round Series A €7m co-led by aws Gründungsfonds + NovaCapital + IGO Innovation |
2024-10-17 |
| Nuclera–SEVERAL: investment, 202410 financing round Series C $75m led by Elevage Medical Technologies (Patient Square Capital) |
2024-10-16 |
| Invios–SEVERAL: investment, 202410 financing round Series A €8.2m incl existing investors + Ligand Pharmaceuticals |
2024-10-15 |
| Booster Therapeutics–SEVERAL: investment, 202410 seed financing round $15m led by Apollo Health Ventures + Novo Holdings |
2024-10-10 |
| Clock Bio–SEVERAL: investment, 202410 seed financing round $5.3m led by LocalGlobe |
2024-10-09 |
| Bayer–Moma Therapeutics: drug discovery, 202410– collab + excl license option €na using KNOMTIC platform to discover small-molecule cancer drugs |
2024-10-08 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
